Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genes.

ABSTRACT:

Background

Gliomas evade current therapies through primary and acquired resistance and the effect of temozolomide is mainly restricted to methylguanin-O6-methyltransferase promoter (MGMT) promoter hypermethylated tumors. Further resistance markers are largely unknown and would help for better stratification.

Methods

Clinical data and methylation profiles from the NOA-08 (104, elderly glioblastoma) and the EORTC 26101 (297, glioblastoma) studies and 398 patients with glioblastoma from the Heidelberg Neuro-Oncology center have been analyzed focused on the predictive effect of DNA damage response (DDR) gene methylation. Candidate genes were validated in vitro.

Results

Twenty-eight glioblastoma 5'-cytosine-phosphat-guanine-3' (CpGs) from 17 DDR genes negatively correlated

SUBMITTER: Kessler T 

PROVIDER: S-EPMC7666733 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature